ABT Looks 22.9% Undervalued on GF Value™ as Dividend Remains Sustainable

gurufocus.com · 2026-09-14

On September 14, 2026, Abbott Laboratories (NYSE: ABT) reversed a six-day losing streak with a 1.21% gain, closing at $103.18. This uptick followed the company'

TickrTrends take: Abbott Laboratories trades at a valuation discount that aligns with TickrTrends' current undervalued assessment of the Healthcare sector company. The sustainability of ABT's dividend alongside the identified valuation gap suggests the stock may present a buying opportunity for investors focused on income-producing holdings at reduced valuations. Observers tracking ABT should monitor whether this discount persists or narrows as market conditions and the company's financial performance evolve.

Read the full story at gurufocus.com →